Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 12/2007

01-08-2007 | Adis Drug Profile

Bevacizumab in First-Line Treatment of Metastatic Breast Cancer

A Viewpoint by David Miles

Author: David Miles

Published in: Drugs | Issue 12/2007

Login to get access

Excerpt

For several decades, the process of angiogenesis has been understood to be a prerequisite for tumour growth and metastasis. Vascular endothelial growth factor (VEGF) is a key angiogenic factor and strategies to target VEGF or its receptor are being evaluated in several tumour types. Bevacizumab, a humanised monoclonal antibody to VEGF, inhibits tumour growth in xenograft models: ‘normalisation’ of existing vasculature and consequent lowering of oncotic pressure within tumours has also been demonstrated to increase delivery of other agents to tumours providing the rational basis for its combination with other agents. …
Literature
1.
Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Sem Oncol 2003; 30 (5 Suppl. 16): 117–24CrossRef
2.
Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23(4): 792–9PubMedCrossRef
Metadata
Title
Bevacizumab in First-Line Treatment of Metastatic Breast Cancer
A Viewpoint by David Miles
Author
David Miles
Publication date
01-08-2007
Publisher
Springer International Publishing
Published in
Drugs / Issue 12/2007
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200767120-00010

Other articles of this Issue 12/2007

Drugs 12/2007 Go to the issue

Adis Drug Profile

Bevacizumab

Leading Article

Antileukotrienes as Adjunctive Therapy in Acute Asthma

Review Article

Current Management of Mantle Cell Lymphoma

Leading Article

Pharmacotherapy of Mood Disorders and Treatment Discontinuation

Adis Drug Evaluation

Aliskiren

Review Article

Infliximab Therapy in Children and Adolescents with Inflammatory Bowel Disease